Hypoxia-sensitive epigenetic regulation of an antisense-oriented lncRNA controls WT1 expression in myeloid leukemia cells.

PloS One
Gregory McCarty, David M Loeb

Abstract

WT1 is a transcription factor expressed in hematopoietic stem cells and in most cases of myeloid leukemia. We investigated the roles of hypoxia and epigenetics in the regulation of WT1 expression in myeloid leukemia cells. WT1 expression correlates with hypomethylation of the CpG island in Intron 1, and pharmacologic demethylation of this CpG island induces WT1 mRNA expression. Hypoxia causes decreases in DNMT expression and activity and increased expression and activity of TET2 and TET3, resulting in demethylation of this CpG island and expression of WT1 mRNA. Demethylation of the CpG island, either from pharmacologic treatment or induction of hypoxia, results in transcription of an antisense-oriented lncRNA, and inhibiting lncRNA expression with shRNA blocks WT1 mRNA expression. These results reveal a novel model of hypoxia-mediated epigenetic gene regulation. In addition, this is the first report that TET2 and TET3, increasingly recognized as important epigenetic regulators of gene expression in stem cells and in cancer cells, can be regulated by hypoxia, providing a solid mechanistic link between hypoxia and epigenetic regulation of gene expression with important implications for the role of hypoxia in stem cell function.

References

Feb 5, 1992·Journal of the National Cancer Institute·H MiwaG F Saunders
Mar 1, 1994·Nature Genetics·Y JinnoN Niikawa
Jun 1, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kay-Dietrich WagnerHolger Scholz
May 10, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kay-Dietrich WagnerHolger Scholz
Oct 17, 2007·Annual Review of Medicine·Einav Nili Gal-YamPeter A Jones
Oct 30, 2007·Epigenetics : Official Journal of the DNA Methylation Society·Siranoush ShahrzadBrenda L Coomber
Sep 3, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin A CheeverLynn M Matrisian
Sep 3, 2009·Journal of Cellular Physiology·Pernilla Eliasson, Jan-Ingvar Jönsson
Sep 16, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela CilloniDavid Grimwade
Jun 15, 2010·Epigenetics : Official Journal of the DNA Methylation Society·Karolina SkowronskiBrenda Coomber
Sep 20, 2011·Cellular Signalling·Andrew Melvin, Sonia Rocha
Dec 6, 2011·Nature Genetics·Grant A ChallenMargaret A Goodell
Feb 13, 2013·Nature Reviews. Genetics·Zachary D Smith, Alexander Meissner
Mar 1, 2013·Science Translational Medicine·Aude G ChapuisPhilip D Greenberg
Mar 15, 2013·Science Translational Medicine·Tao DaoDavid A Scheinberg

❮ Previous
Next ❯

Citations

Jan 26, 2016·Molecular Aspects of Medicine·Hani ChoudhryAlan McIntyre
Sep 6, 2015·Gene·Ya-Nan ChangWei Hong
Nov 27, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jun DongBilian Jin
Nov 22, 2015·Briefings in Functional Genomics·Hani Choudhry, David R Mole
May 18, 2017·Future Oncology·Su-Rui ShengXin-Hua Liang
Dec 22, 2016·Experimental Hematology & Oncology·Shuyong Wei, Kankan Wang
Aug 11, 2017·Antioxidants & Redox Signaling·Xue WuMircea Ivan
Feb 13, 2019·International Journal of Molecular Sciences·Gabriela Marisol Cruz-MirandaSilvia Jiménez-Morales
Jul 25, 2019·Frontiers in Oncology·Michelle NgJan-Henning Klusmann
Aug 10, 2017·Journal of Biomedical Science·Jing-Wen Shih, Hsing-Jien Kung
Jan 4, 2018·Blood Advances·Chi-Yuan YaoHwei-Fang Tien
Apr 12, 2019·Briefings in Bioinformatics·Saman ZeeshanZeeshan Ahmed
Jun 24, 2017·Nature Communications·Jing-Wen ShihHsing-Jien Kung
May 7, 2020·Journal of Biomedical Science·Tse-Chun KuoJing-Wen Shih
Aug 9, 2020·Experimental Biology and Medicine·Mieko MatsuyamaShigemi Matsuyama
Aug 11, 2018·Nature Communications·Tracy A O'MaraDeborah J Thompson
Oct 24, 2019·Pathology, Research and Practice·Lining HuangXingming Jiang
Jan 8, 2021·The FEBS Journal·Rugile MatuleviciuteIosifina P Foskolou
Jul 25, 2021·International Journal of Molecular Sciences·Nicole Wagner, Kay-Dietrich Wagner
Jun 1, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Guanghui HuWei Zhai
Sep 28, 2021·Journal of Cellular Physiology·Anuradha KirtoniaManoj Garg
Jan 13, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Andrea KapinovaJan Danko

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
immunoprecipitation
coronary artery ligation
bone marrow aspirations
electrophoresis

Software Mentioned

GraphPad
Prism

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Epigenetics and Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved